Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.3.0.814
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Operating expenses:        
Research and development $ 407,571 $ 111,600 $ 1,333,118 $ 421,903
General and administrative 946,180 480,450 2,668,513 1,646,910
Total operating expenses 1,353,751 592,050 4,001,631 2,068,813
Other income (expense), net:        
Research and development tax credit 0 (9,703)   15,812
Interest income 202 89 621 720
Extinguishment of research liability   240,000   240,000
Interest expense   (169,831) (1,920,146) (264,040)
Change in warrant liability 0 881,753 223,172 876,753
Other income (expense), net (1,987) 0 9  
Total other income (expense), net (1,785) 942,308 (1,696,344) 869,245
Net (loss) income (1,355,536) 350,258 (5,697,975) (1,199,568)
Deemed dividend on preferred stock 0 0 (8,222,008)  
Net income attributable to non-controlling interests 0 (40,666) (5,177) (157,928)
Net (loss) income attributable to Eyegate Pharmaceuticals, Inc. common stockholders $ (1,355,536) $ 309,592 $ (13,925,160) $ (1,357,496)
Net loss per common share - basic and diluted $ (0.19) $ 1.59 $ (2.46) $ (7.13)
Weighted average shares outstanding - basic and diluted 7,161,777 194,822 5,661,153 190,516
Net (loss) income $ (1,355,536) $ 350,258 $ (5,697,975) $ (1,199,568)
Other comprehensive income (loss):        
Foreign currency translation adjustments (6,741) (2,610) 74,572 (7,687)
Comprehensive loss (1,362,277) 347,648 (5,623,403) (1,207,255)
Less:        
Net income attributable to non-controlling interests 0 (40,666) (5,177) (157,928)
Other comprehensive (income) loss attributable to non-controlling interests 0 86,765 32,967 55,639
Comprehensive (income) loss attributable to non-controlling interests 0 46,099 27,790 (102,289)
Comprehensive (loss) income attributable to Eyegate Pharmaceuticals, Inc. stockholders $ (1,362,277) $ 393,747 $ (5,595,613) $ (1,309,544)